Literature DB >> 34613430

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.

Conor H Murray1, Ilaria Tare1, Claire M Perry1, Michael Malina1, Royce Lee1, Harriet de Wit2.   

Abstract

RATIONALE: Classical psychedelics, including psilocybin and lysergic acid diethylamide (LSD), are under investigation as potential therapeutic agents in psychiatry. Whereas most studies utilize relatively high doses, there are also reports of beneficial effects of "microdosing," or repeated use of very low doses of these drugs. The behavioral and neural effects of these low doses are not fully understood.
OBJECTIVES: To examine the effects of LSD (13 μg and 26 μg) versus placebo on resting-state electroencephalography (EEG) and event-related potential (ERP) responses in healthy adults.
METHODS: Twenty-two healthy men and women, 18 to 35 years old, participated in 3 EEG sessions in which they received placebo or LSD (13 μg and 26 μg) under double-blind conditions. During each session, participants completed drug effect and mood questionnaires at hourly intervals, and physiological measures were recorded. During expected peak drug effect, EEG recordings were obtained, including resting-state neural oscillations in scalp electrodes over default mode network (DMN) regions and P300, N170, and P100 ERPs evoked during a visual oddball paradigm.
RESULTS: LSD dose-dependently reduced oscillatory power across delta, theta, alpha, beta, and gamma frequency bands during both eyes closed and eyes open resting conditions. During the oddball task, LSD dose-dependently reduced ERP amplitudes for P300 and N170 components and increased P100 latency. LSD also produced dose-related increases in positive mood, elation, energy, and anxiety and increased heart rate and blood pressure. On a measure of altered states of consciousness, LSD dose-dependently increased Blissful State, but not other indices of perceptual or sensory effects typical of psychedelic drugs. The subjective effects of the drug were not correlated with the EEG measures.
CONCLUSIONS: Low doses of LSD produced broadband cortical desynchronization over the DMN during resting state and reduced P300 and N170 amplitudes, patterns similar to those reported with higher doses of psychedelics. Notably, these neurophysiological effects raise the possibility that very low doses of LSD may produce subtle behavioral and perhaps therapeutic effects that do not rely on the full psychedelic experience.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  EEG; ERP; LSD; Microdose; Psychedelic

Mesh:

Substances:

Year:  2021        PMID: 34613430     DOI: 10.1007/s00213-021-05991-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

Review 1.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex.

Authors:  Jean-Claude Béïque; Mays Imad; Ljiljana Mladenovic; Jay A Gingrich; Rodrigo Andrade
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

Review 3.  The standardized psychometric assessment of altered states of consciousness (ASCs) in humans.

Authors:  A Dittrich
Journal:  Pharmacopsychiatry       Date:  1998-07       Impact factor: 5.788

4.  Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.

Authors:  Anya K Bershad; Katrin H Preller; Royce Lee; Sarah Keedy; Jamie Wren-Jarvis; Michael P Bremmer; Harriet de Wit
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-12-20

Review 5.  d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.

Authors:  Danilo De Gregorio; Justine P Enns; Nicolas A Nuñez; Luca Posa; Gabriella Gobbi
Journal:  Prog Brain Res       Date:  2018-08-31       Impact factor: 2.453

6.  Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.

Authors:  Anya K Bershad; Scott T Schepers; Michael P Bremmer; Royce Lee; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2019-06-03       Impact factor: 13.382

7.  The effects of dexamphetamine on the resting-state electroencephalogram and functional connectivity.

Authors:  Matthew A Albrecht; Gareth Roberts; Greg Price; Joseph Lee; Rajan Iyyalol; Mathew T Martin-Iverson
Journal:  Hum Brain Mapp       Date:  2015-11-18       Impact factor: 5.038

8.  Synchronous oscillatory neural ensembles for rules in the prefrontal cortex.

Authors:  Timothy J Buschman; Eric L Denovellis; Cinira Diogo; Daniel Bullock; Earl K Miller
Journal:  Neuron       Date:  2012-11-21       Impact factor: 17.173

9.  Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.

Authors:  Robin L Carhart-Harris; David Erritzoe; Tim Williams; James M Stone; Laurence J Reed; Alessandro Colasanti; Robin J Tyacke; Robert Leech; Andrea L Malizia; Kevin Murphy; Peter Hobden; John Evans; Amanda Feilding; Richard G Wise; David J Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

10.  Neural correlates of the LSD experience revealed by multimodal neuroimaging.

Authors:  Robin L Carhart-Harris; Suresh Muthukumaraswamy; Leor Roseman; Mendel Kaelen; Wouter Droog; Kevin Murphy; Enzo Tagliazucchi; Eduardo E Schenberg; Timothy Nest; Csaba Orban; Robert Leech; Luke T Williams; Tim M Williams; Mark Bolstridge; Ben Sessa; John McGonigle; Martin I Sereno; David Nichols; Peter J Hellyer; Peter Hobden; John Evans; Krish D Singh; Richard G Wise; H Valerie Curran; Amanda Feilding; David J Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-11       Impact factor: 12.779

View more
  1 in total

1.  Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.

Authors:  Carla Pallavicini; Enzo Tagliazucchi; Federico Cavanna; Stephanie Muller; Laura Alethia de la Fuente; Federico Zamberlan; Matías Palmucci; Lucie Janeckova; Martin Kuchar
Journal:  Transl Psychiatry       Date:  2022-08-02       Impact factor: 7.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.